Insider Trends: 90-Day Insider Selling Trend Prolonged at Denali Therapeutics
04:48 PM EST, 02/05/2021 (MT Newswires) -- On Feb 04, 2021, Dr Alexander O Schuth, COO and Secretary, reported a sale of 10,000 shares in Denali Therapeutics (DNLI) for $678,361. Following the Form 4 filing with the SEC, Dr Schuth has control over a total of 545,248 shares of the company, with 10,686 shares held directly and 534,562 controlled indirectly. The market value of the direct and indirect holdings, based on the prior-day closing price, is approximately $38.0 million.
During the most recent 90-day period, prior to the date of this filing, there have been 8 transactions reported to the SEC, all of which have been sales and have resulted in the disposition of 744,703 company shares by insiders. Relative to the preceding 90-day window of time, there were 11 transactions from 5 insiders which resulted in the net disposition of 1,445,869 shares.
This represents a lower level of transactions than the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Peer group activity averaged 56.2 transactions per company, with company insiders acquiring on average 24,487 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1714899/000120919121008103/xslF345X03/doc4.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.